share_log

CRISPR Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

CRISPR Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

CRISPR Therapeutics | S-3ASR：“知名成熟發行人”證券註冊聲明
美股sec公告 ·  08/06 05:27
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG, a leading gene editing company, has announced the availability of up to $378,641,978 of its common shares for sale through an Open Market Sale AgreementSM with Jefferies LLC. The shares will be offered at market prices and sold on The Nasdaq Global Market under the ticker symbol 'CRSP'. The proceeds from the sale are intended to fund research and clinical development of pipeline candidates, platform extensions, manufacturing infrastructure, working capital, and general corporate purposes. The company has previously issued 1,642,636 common shares under the Sales Agreement and plans to use the additional funds to continue advancing its CRISPR/Cas9-based therapeutics, including the landmark CRISPR-based therapy, CASGEVY, which was approved in 2023.
CRISPR Therapeutics AG, a leading gene editing company, has announced the availability of up to $378,641,978 of its common shares for sale through an Open Market Sale AgreementSM with Jefferies LLC. The shares will be offered at market prices and sold on The Nasdaq Global Market under the ticker symbol 'CRSP'. The proceeds from the sale are intended to fund research and clinical development of pipeline candidates, platform extensions, manufacturing infrastructure, working capital, and general corporate purposes. The company has previously issued 1,642,636 common shares under the Sales Agreement and plans to use the additional funds to continue advancing its CRISPR/Cas9-based therapeutics, including the landmark CRISPR-based therapy, CASGEVY, which was approved in 2023.
CRISPR Therapeutics AG，一家領先的基因編輯公司，宣佈通過與Jefferies LLC簽訂的公開市場銷售協議向市場提供多達378,641,978美元的普通股。這些股票將以市場價格出售，並在納斯達克全球市場逐筆明細爲“CRSP”的股票下進行交易。銷售所得將用於資助管線候選研究和臨床開發、平台擴展、製造基礎設施、營運資金和一般公司用途。該公司先前已經發放了1,642,636股普通股，並計劃使用額外的資金繼續推進其CRISPR / Cas9基於治療，包括標誌性的CRISPR基於治療，CASGEVY，該治療已於2023年獲得批准。
CRISPR Therapeutics AG，一家領先的基因編輯公司，宣佈通過與Jefferies LLC簽訂的公開市場銷售協議向市場提供多達378,641,978美元的普通股。這些股票將以市場價格出售，並在納斯達克全球市場逐筆明細爲“CRSP”的股票下進行交易。銷售所得將用於資助管線候選研究和臨床開發、平台擴展、製造基礎設施、營運資金和一般公司用途。該公司先前已經發放了1,642,636股普通股，並計劃使用額外的資金繼續推進其CRISPR / Cas9基於治療，包括標誌性的CRISPR基於治療，CASGEVY，該治療已於2023年獲得批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。